The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Effects of Methylphenidate on the Catecholaminergic System in Attention-Deficit/Hyperactivity Disorder
Abstract
Stimulants are part of the standard-of-care treatment for attention-deficit/hyperactivity disorder (ADHD). Methylphenidate, with a history of use spanning approximately 5 decades, is a first-line stimulant treatment for ADHD. Methylphenidate chiefly affects the prefrontal cortex and striatum, the mechanism of action being modulation of catecholaminergic tone. Methylphenidate treatment produces an increase in dopamine (DA) signaling through multiple actions, including blockade of the DA reuptake transporter and amplification of DA response duration, disinhibition of DA D2 autoreceptors and amplification of DA tone, and activation of D1 receptors on the postsynaptic neuron. The actions of methylphenidate may also be mediated by stimulation of the noradrenergic alpha2 receptor and DA D1 receptor in the cortex. The role of other neurotransmitters such as histamine, acetylcholine, serotonin, and alpha-agonists in modulating catecholamine pathophysiology in ADHD and ADHD treatment needs to be elucidated. Overall, the changes in catecholaminergic tone clinically manifest as improvements in attention deficit, distractibility, and motor hyperactivity in patients with ADHD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DA accumulation after MPH blockade of DAT induces disinhibition (upregulation) of the presynaptic receptor DRD2 (dopaminergic neuron) and activates D1 receptors on the postsynaptic neuron that uptake DA, continuing the neuronal transmission and therefore improving attention, focus and organized thoughts and actions [172, 173].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [173]
In the citing paper
“Psychostimulants, such as methylphenidate, followed by dexamphetamines, are first-line pharmacologic treatment for ADHD and reduce symptoms in about 70% of patients 11, 12.”
From Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis (2014) · cites this paper as [11]
In the citing paper
“The therapeutic dose of MPH works primarily via (1) increasing DA signaling through multiple actions, including DAT blockade in the PFC, and significantly enhancing extracellular DA release in the striatum (Volkow et al., 2002; Wilens, 2008) and (2) indirectly increasing NE actions through blockade of its transporters (Berridge et al., 2006).”
From The Effects of Methylphenidate on Goal-directed Behavior in a Rat Model of ADHD (2015) · cites this paper as Wilens, 2008
In the citing paper
“there is increasing evidence of the relevance of catecholaminergic modulation in limbic regions such as ventral striatum (perhaps also amygdala and hippocampus) in mediating the motivation enhancing effects of stimulant drugs (Lehmann et al, 2003;Wilens, 2008).”
From Understanding the Effects of Stimulant Medications on Cognition in Individuals with Attention-Deficit Hyperactivity Disorder: A Decade of Progress (2011) · cites this paper as Wilens, 2008
In the citing paper
“Several brain regions and circuits are involved in the orchestration of specific cognitive processes that impact attention; these circuits are modulated by the catecholaminergic system and thus are affected and modulated by stimulant medications (Wilens, 2008).”
From Understanding the Effects of Stimulant Medications on Cognition in Individuals with Attention-Deficit Hyperactivity Disorder: A Decade of Progress (2011) · cites this paper as Wilens, 2008
Citations
Cites
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Two dopamine receptors: Biochemistry, physiology and pharmacology
Stoof, J. C., & Kebabian, J. W. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90519-8 · Cited by 939
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Modulation of neurotransmitter release by presynaptic autoreceptors
Starke, K., Gothert, M., & Kilbinger, H. (1989) · Physiological Reviews · doi:10.1152/physrev.1989.69.3.864 · Cited by 925
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Trends in the Prescribing of Psychotropic Medications to Preschoolers
Zito, J. M. (2000) · JAMA · doi:10.1001/jama.283.8.1025 · Cited by 863
Vaidya, C. J., Austin, G., Kirkorian, G., Ridlehuber, H. W., Desmond, J. E., Glover, G. H., & Gabrieli, J. D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14494 · Cited by 845
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gerasimov, M., Maynard, L., Ding, Y.-S., Gatley, S. J., Gifford, A., & Franceschi, D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-j0001.2001 · Cited by 770
Dopamine transporter density in patients with attention deficit hyperactivity disorder
Dougherty, D. D., Bonab, A. A., Spencer, T. J., Rauch, S. L., Madras, B. K., & Fischman, A. J. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04030-1 · Cited by 684
Research works printed but not linked: 2
- Madras, 1998, Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain., Synapse, 29, 105, 10.1002/(SICI)1098-2396(199806)29:2<105::AID-SYN2>3.0.CO;2-B · DOI
- Madras, 1998, Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain., Synapse, 29, 116, 10.1002/(SICI)1098-2396(199806)29:2<116::AID-SYN3>3.0.CO;2-A · DOI
Cited by
del Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
Rubia, K., Halari, R., Cubillo, A., Mohammad, A.-M., Brammer, M., & Taylor, E. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.013 · Cited by 393
Rubia, K., Alegria, A. A., Cubillo, A. I., Smith, A. B., Brammer, M. J., & Radua, J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.016 · Cited by 315
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
Treatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Metadata
- Authors
- Wilens, T. E.
- Affiliations
- Harvard University (US)
- Corresponding author
- Wilens, Timothy E.
- ORCID
- Wilens, Timothy E.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-06
- Volume
- 28
- Issue
- 3
- Pages
- S46-S53
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2077465062
- Cited by
- 269
- References
- 75
- Citations by year
- 2026: 11 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 14 · 2018: 17 · 2017: 16 · 2016: 22 · 2015: 19 · 2014: 20 · 2013: 15 · 2012: 29
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- methylphenidate, attention deficit hyperactivity disorder, catecholaminergic system, dopamine signaling, dopamine D2 autoreceptors, dopamine D1 receptor, prefrontal cortex, striatum, histamine, acetylcholine, serotonin, alpha-adrenergic agonists
- MeSH terms
- Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Corpus Striatum, Dopamine, Humans, Methylphenidate, Nerve Net, Synaptic Transmission, Norepinephrine, Signal Transduction, Prefrontal Cortex, Receptors, Dopamine D1, Receptors, Dopamine D2, Receptors, Adrenergic, alpha-2, Dopamine Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Methylphenidate on the Catecholaminergic System in Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.1097/jcp.0b013e318173312f
- The paper
- Wilens, T. E. (2008). Effects of Methylphenidate on the Catecholaminergic System in Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318173312f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.